Evidence map›Paper›PMID 36907221›Full record

Trial reportBrain : a journal of neurology2023

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.

James L Mitchell, Hannah S Lyons, Jessica K Walker, Andreas Yiangou, Olivia Grech, Zerin Alimajstorovic, Nigel H Greig, Yazhou Li, Georgios Tsermoulas, Kristian Brock and 2 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Brain : a journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 7 pooled it
28.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 7 syntheses or guidelines pooled it, 138 citations in OpenAlex.

  1. Risk Reduction of Recurrent Cerebrospinal Fluid Leaks With Postoperative Intracranial Pressure Management: A Systematic Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Pooled it
  2. Therapeutic role of GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

James L MitchellUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.ORCID 0000-0001-6785-9352
Hannah S LyonsUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.
Jessica K WalkerUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.
Andreas YiangouUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.
Olivia GrechUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.
Zerin AlimajstorovicUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.ORCID 0000-0001-5622-8301
Nigel H GreigDrug Design & Development Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Yazhou LiDrug Design & Development Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Georgios TsermoulasUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.
Kristian BrockCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK.
Susan P MollanUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.ORCID 0000-0002-6314-4437
Alexandra J SinclairUniversity of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK.ORCID 0000-0003-2777-5132
University Hospitals Birmingham NHS Foundation Trust · GBUniversity of Birmingham · GBNational Institutes of Health · USCancer Research UK Clinical Trials Unit · GBNIHR Surgical Reconstruction and Microbiology Research Centre · GB

Funding

Neuroprotective role of GLP-1 receptor agonists (Neurodegenerative disorders & Alzheimer's disease)ZIAAG000333 · NIA · NATIONAL INSTITUTE ON AGING · PI GREIG, NIGEL H. · 2009 to 2025
$10.9M
Department of HealthMedical Research Council MR/K015184/1
6 · The paper itself

Abstract

Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 (GLP-1) receptor signalling. Here, we translate these findings into patients by conducting a randomized, placebo-controlled, double-blind trial to assess the effect of exenatide, a GLP-1 receptor agonist, on intracranial pressure in idiopathic intracranial hypertension. Telemetric intracranial pressure catheters enabled long-term intracranial pressure monitoring. The trial enrolled adult women with active idiopathic intracranial hypertension (intracranial pressure >25 cmCSF and papilloedema) who receive subcutaneous exenatide or placebo. The three primary outcome measures were intracranial pressure at 2.5 h, 24 h and 12 weeks and alpha set a priori at less than 0.1. Among the 16 women recruited, 15 completed the study (mean age 28 ± 9, body mass index 38.1 ± 6.2 kg/m2, intracranial pressure 30.6 ± 5.1 cmCSF). Exenatide significantly and meaningfully lowered intracranial pressure at 2.5 h -5.7 ± 2.9 cmCSF (P = 0.048); 24 h -6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks -5.6 ± 3.0 cmCSF (P = 0.058). No serious safety signals were noted. These data provide confidence to proceed to a phase 3 trial in idiopathic intracranial hypertension and highlight the potential to utilize GLP-1 receptor agonist in other conditions characterized by raised intracranial pressure.

Indexed as

Diabetes Mellitus, Type 2Pseudotumor CerebriAdultExenatideFemaleGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsPeptidesVenomsYoung AdultExenatideGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsPeptidesVenomscerebrospinal fluidglucagon-like peptide 1idiopathic intracranial hypertensionintracranial pressuretelemetric monitor

Identifiers

PMID36907221
PMCPMC10151178
OpenAlexW4323981273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.